Zynerba Pharmaceuticals, Inc.

NasdaqCM:ZYNE Stock Report

Market Cap: US$65.6m

Zynerba Pharmaceuticals Dividends and Buybacks

Dividend criteria checks 0/6

Zynerba Pharmaceuticals does not have a record of paying a dividend.

Key information

n/a

Dividend yield

-8.7%

Buyback Yield

Total Shareholder Yield-8.7%
Future Dividend Yieldn/a
Dividend Growthn/a
Next dividend pay daten/a
Ex dividend daten/a
Dividend per sharen/a
Payout ration/a

Recent dividend and buyback updates

No updates

Recent updates

Is Zynerba Pharmaceuticals (NASDAQ:ZYNE) In A Good Position To Deliver On Growth Plans?

Mar 01
Is Zynerba Pharmaceuticals (NASDAQ:ZYNE) In A Good Position To Deliver On Growth Plans?

Is Zynerba Pharmaceuticals (NASDAQ:ZYNE) In A Good Position To Invest In Growth?

Nov 11
Is Zynerba Pharmaceuticals (NASDAQ:ZYNE) In A Good Position To Invest In Growth?

Zynerba stock rises on US patent for cannabidiol Zygel's use for Fragile X syndrome

Oct 06

Zynerba Pharmaceuticals GAAP EPS of -$0.24 misses by $0.01

Aug 10

We Think Zynerba Pharmaceuticals (NASDAQ:ZYNE) Can Afford To Drive Business Growth

Jul 22
We Think Zynerba Pharmaceuticals (NASDAQ:ZYNE) Can Afford To Drive Business Growth

Zynerba inks equity funding contract of up to $20M with Lincoln Park Capital

Jul 21

Here's Why We're Watching Zynerba Pharmaceuticals' (NASDAQ:ZYNE) Cash Burn Situation

Mar 23
Here's Why We're Watching Zynerba Pharmaceuticals' (NASDAQ:ZYNE) Cash Burn Situation

We Think Zynerba Pharmaceuticals (NASDAQ:ZYNE) Can Afford To Drive Business Growth

Dec 02
We Think Zynerba Pharmaceuticals (NASDAQ:ZYNE) Can Afford To Drive Business Growth

We Think Zynerba Pharmaceuticals (NASDAQ:ZYNE) Can Afford To Drive Business Growth

May 27
We Think Zynerba Pharmaceuticals (NASDAQ:ZYNE) Can Afford To Drive Business Growth

Zynerba Pharma shares slip 10% on Zygel update in Fragile X syndrome

Dec 17

Is Zynerba Pharmaceuticals (NASDAQ:ZYNE) In A Good Position To Invest In Growth?

Nov 23
Is Zynerba Pharmaceuticals (NASDAQ:ZYNE) In A Good Position To Invest In Growth?

Zynerba Pharmaceuticals EPS beats by $0.12

Nov 09

Zynerba Zygel Remains A Huge Part Of The Company's Pipeline Despite Setback

Oct 29

Stability and Growth of Payments

Fetching dividends data

Stable Dividend: Insufficient data to determine if ZYNE's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ZYNE's dividend payments have been increasing.


Dividend Yield vs Market

Zynerba Pharmaceuticals Dividend Yield vs Market
How does ZYNE dividend yield compare to the market?
SegmentDividend Yield
Company (ZYNE)n/a
Market Bottom 25% (US)1.4%
Market Top 25% (US)4.3%
Industry Average (Pharmaceuticals)2.4%
Analyst forecast (ZYNE) (up to 3 years)n/a

Notable Dividend: Unable to evaluate ZYNE's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate ZYNE's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate ZYNE's payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as ZYNE has not reported any payouts.


Discover strong dividend paying companies